# Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy

> **NCT03493789** · PHASE1 · COMPLETED · sponsor: **Emory University** · enrollment: 19 (actual)

## Conditions studied

- Stage I Lung Cancer
- Stage I Non-Small Cell Lung Cancer AJCC v7
- Stage IA Non-Small Cell Lung Carcinoma AJCC v7
- Stage IB Non-Small Cell Lung Carcinoma AJCC v7
- Stage II Lung Cancer
- Stage II Non-Small Cell Lung Cancer AJCC v7
- Stage IIA Non-Small Cell Lung Carcinoma AJCC v7
- Stage IIB Non-Small Cell Lung Carcinoma AJCC v7

## Interventions

- **DRUG:** Fludeoxyglucose F-18
- **PROCEDURE:** Positron Emission Tomography (PET)
- **RADIATION:** Stereotactic Body Radiation Therapy (SBRT)

## Key facts

- **NCT ID:** NCT03493789
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-04-13
- **Primary completion:** 2019-03-19
- **Final completion:** 2019-03-19
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2023-10-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03493789

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03493789, "Fludeoxyglucose F-18-PET in Planning Lung Cancer Radiation Therapy". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT03493789. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*